Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Over 5000 rare genetic diseases collectively affect 1 in 12 Canadians. For these disorders about 10% of patients share a common mutation type that introduces a premature termination codon (PTC) in the gene and results in truncated and non-functional protein. The previously found PTC suppressors have limited effect or unacceptable side effects. The goal of my project is to use a new approach to discover novel chemicals that suppress PTC with therapeutic potential for multiple genetic disorders. I will test over 300,000 chemicals in a yeast-based screening assay to detect the few that can act as PTC suppressors. I will test the activity of these chemicals in cells derived from patients with various genetic disorders and bearing PTC. Finally I will elucidate the mechanism of action of the active compounds. The screening section of this proposal will be performed in collaboration with the Centre for Drug Research and Development (CDRD).
Dr. Michel Roberge
Alireza Baradaran-Heravi
Centre for Drug Research and Development
Biochemistry / Molecular biology
Pharmaceuticals
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.